BRIEF published on 07/06/2026 at 07:05, 1 month 10 days ago ReproNovo Begins EU Phase 2 Trial for Embryo Implantation Treatment ReproNovo RPN-002 Embryo Implantation NORDIC Trial Assisted Reproductive Technology
BRIEF published on 07/06/2026 at 07:05, 1 month 10 days ago ReproNovo lance un essai clinique de phase 2 dans l'UE pour son traitement d'implantation d'embryons. ReproNovo RPN-002 Implantation D'embryons Essai Nordique Techniques De Procréation Assistée
PRESS RELEASE published on 07/06/2026 at 07:00, 1 month 10 days ago ReproNovo Announces First Participant Dosed In EU Phase 2 Trial Of RPN-002 Embryo Implantation ReproNovo doses first participant in EU Phase 2 trial of RPN-002 for embryo implantation, aiming to increase IVF success rates with oxytocin receptor antagonist ReproNovo RPN-002 Embryo Implantation EU Phase 2 Trial IVF Success
BRIEF published on 03/20/2026 at 13:05, 4 months 27 days ago ReproNovo Appoints Mark Altmeyer as Chairman of the Board Biopharmaceutical Fertility Leadership ReproNovo Mark Altmeyer
BRIEF published on 03/20/2026 at 13:05, 4 months 27 days ago ReproNovo nomme Mark Altmeyer président du conseil d'administration Biopharmaceutique Direction ReproNovo Mark Altmeyer Fécondité
PRESS RELEASE published on 03/20/2026 at 13:00, 4 months 27 days ago REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD ReproNovo appoints Mark Altmeyer as Chairman of the Board. Altmeyer brings 35+ years of biopharma leadership experience across multiple therapeutic areas Chairman Fertility Biopharma ReproNovo Mark Altmeyer
BRIEF published on 09/30/2025 at 07:05, 10 months 16 days ago ReproNovo Gains Approval for RPN-001 Clinical Trial in China Clinical Trial China Approval ReproNovo Reproductive Medicine RPN-001
BRIEF published on 09/30/2025 at 07:05, 10 months 16 days ago ReproNovo obtient l'approbation pour l'essai clinique RPN-001 en Chine Essai Clinique ReproNovo RPN-001 Approbation De La Chine Médecine De La Reproduction
PRESS RELEASE published on 09/30/2025 at 07:00, 10 months 16 days ago ReproNovo Announces Clinical Trial Approval Notice for RPN-001 in China ReproNovo receives approval for RPN-001 Phase 1 trial in China from NMPA, a key step in global development for male infertility treatment. Company expanding clinical programs in the U.S. and China China Male Infertility Clinical Trial ReproNovo RPN-001
BRIEF published on 07/01/2025 at 07:05, 1 year 1 month ago ReproNovo Initiates Phase 2 Trial for Male Infertility Drug in the U.S. Male Infertility Phase 2 Trial ReproNovo RPN-001 Low Testosterone
Published on 08/15/2026 at 00:15, 1 day 22 hours ago Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 1 day 23 hours ago AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:00, 1 day 23 hours ago Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
Published on 08/16/2026 at 19:40, 3 hours 10 minutes ago APIC delivers 55% EBITDA growth in the first half of 2026, reaching USD 44 million
Published on 08/16/2026 at 13:40, 9 hours 10 minutes ago Ajax says goodbye to Godts with a classy message in Paris: THE FUTURE BELONGS TO YOUNG GODTS
Published on 08/16/2026 at 09:45, 13 hours 5 minutes ago Ragnarok Zero: Global Set to Officially Launch on August 18
Published on 08/16/2026 at 06:15, 16 hours 35 minutes ago GARVEE met en avant les essentiels pour la maison et le jardin à l’approche de la transition entre la fin de l’été et le début de l’automne
Published on 08/16/2026 at 06:15, 16 hours 35 minutes ago Garvee Spotlights Home & Garden Essentials for the Late-Summer to Early-Autumn Transition
Published on 08/13/2026 at 18:00, 3 days 4 hours ago Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 5 days 5 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 5 days 5 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 6 days 4 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 6 days 4 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
